Amantadine for COVID-19: A randomized, placebo controlled, double-blinded, clinical trial

Copenhagen University Hospital, Hvidovre , Capital Region0 个研究点目标入组 242 人开始时间: 2021年3月29日最近更新: 2022年5月23日

试验速览

暂无简介。

•?Population at risk of developing severe COVID-19, defined as either:
•Age = 40 years of age
•Age = 18 years of age and at least one known comorbidity
•Age = 18 years of age and a BMI = 30
•?COVID-19 disease confirmed by the presence of SARS-CoV-2 nucleic acid by polymerase chain reaction (PCR) within 5 days prior to inclusion.
•?For women of childbearing age (defined as non-sterile premenopausal women): Negative pregnancy test and willingness to use contraceptive during the study period (90 days)
•?Provision of informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 121
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 121

•?Current hospitalization
•?Allergy to amantadine hydrochloride, rimantadine or inactive ingredients.
•?Known history of:
•Untreated narrow-angle glaucoma
•Kidney disease with eGFR < 35 ml/min
•Heart failure, proarrhythmic conditions, ventricular arrhythmias.
•Parkinson’s disease
•Gastric ulcer
•Liver Disease
•Hereditary galactose intolerance, lactose intolerance or glucose/galactose malabsorption
•?Current use of:
•Neuroleptics/antipsychotics/ levodopa
•Anticholinergics
•?Concurrent malignancy requiring chemotherapy
•?Pregnancy and breastfeeding

发起方

Copenhagen University Hospital, Hvidovre , Capital Region